Roundup: $ 10 billion deal ends majority of proceedings against Bayer

An agreement was reached ending a dispute between users of Roundup and Bayer, the German group announced. The firm has pledged between $ 10.1 billion and $ 10.9 billion to end procedures launched by nearly 100,000 Americans who have suffered from cancer due to their exposure to Roundup, a herbicide. based on glyphosate produced by Monsanto.

The German chemical and pharmaceutical group is trying to end the lawsuits in the United States against Roundup and other glyphosate products, which it inherited when it bought Monsanto for 63 billion dollars, completed in 2018.

>> Read: Ten things to know about glyphosate

The agreement does not cover all complaints

The settlement announced on Wednesday does not resolve all disputes, Bayer said it relates to about 75% of proceedings in the United States "which concern about 125,000 complaints in total," Bayer said in a statement.

The agreement "resolves current litigation and establishes a clear mechanism to manage the risks of potential future litigation," the statement said.

$ 10 billion to compensate the American victims of @monsanto @Bayer_FR. Great precedent for other victims and all those who fight #glyphosate and those who authorize it

These "potential future cases will be governed by a 'class agreement' subject to court approval. The agreement includes the creation of a class of potential future plaintiffs and the creation of an independent class scientific committee."

>> Read: France to withdraw 36 glyphosate products from sale

Bayer will continue to market Roundup and does not intend to state on its packaging that it may cause cancer.

With Reuters 

The France 24 week summary invites you to come back to the news that marked the week

Take international news everywhere with you! Download the France 24 app